All News
mTOR Inhibition with Sirolimus Effective in Lupus
Lancet reports that 12 months of sirolimus treatment is associated with improvement in lupus disease activity presumeably by correction of pro-inflammatory T-cell activity.
Read Article
Novel Approach to Knee Osteoarthritis Pain
Geniculate artery embolization was found to dampen knee pain arising from osteoarthritis, according to interim study results presented at the 2018 annual meeting of the Society of Interventional Radiology.
Read Article
Time to Rethink Gout as a Chronic Disease
The current issue of JAMA has a perspective article on Gout’s bad rap as dietary disease rather than the complex, chronic inflammatory disorder that is ineffectively treated in many.
Read Article
Using Synovial Tissue Biopsies to Develop Precision Medicine for Rheumatoid Arthritis
Researchers at Northwestern University have used ultrasound-guided tissue biopsy from the joints to analyze the genes of tissue macrophages with the hope that transcriptional profiling of synovial macrophages may be correlated with clinical parameters or drug responsiveness in rheumatoi
Read Article
Repeat Malignancy Unlikely with Biologic Therapy
Research from the Danish biologics registry shows that the use of a biologic in patients with a history of a primary cancer does not increase the risk of a second malignant neoplasm (SMN) or mortality in rheumatoid arthritis (RA) patients.
Read Article
The RheumNow Week in Review - 16 March 2018
Dr. Jack Cush reviews the highlights from the news, journals and major meetings. Bigtime rheumatologic lessons with tales from intestinal crypts, the friendly skies & the hips of hockey players. Also the microbiome and lupus, benefits of ENT findings with GPA and rare risk of opportunistic infections with biologics.
Read Article
Opportunistic Infections in RA Rare with Biologics
The British Society for Rheumatology Biologics Register for Rheumatoid Arthritis has studied nearly 20,000 patients and observed that there is no substantially different risk of opportunistic infections between different biologics.
Read Article
CARES Study- More CV Deaths with Febuxostat
The CARES study was presented Monday at the American College of Cardiology meeting in Orlando and finds that while the rates of all major cardiovascular (CV) events were comparable between febuxostat or allopurinol, there were more CV deaths with febuxostat.
Read Article
The RheumNow Week in Review - 9 March 2018
Dr. Jack Cush reviews highlights, news and recent research published this past week on RheumNow.com. This week's report includes news on new regulatory changes, new indication for tofacitinib, the rise and deficits of opioids and the benefits of fish and bariatric surgery.
Read Article
FDA Panel Votes to Favor High Dose Xeljanz in Ulcerative Colitis
Yesterday a FDA advisory panel voted 15-0 in favor of approving Xeljanz (tofacitinib) 10 mg bid for patients with moderate to severe ulcerative colitis.
Read Article
Biologics in Pregnancy: Are They Safe?
Exposure to biologic therapies among women with autoimmune diseases was not associated with increased risks of preterm delivery or having small for gestational age babies, a population-based Canadian study found.
Read Article
DSB – Safety Updates & Drug Shortages – March 2018
This edition of RheumNow's Drug Safey Bulletin includes drug safety news, FDA updates, FDA safety labeling changes and reported drug shortages.
Read Article
Opioid Overdoses Jump 30% in 2017
The CDC released new information yesterday showing that emergency department (ED) visits for opioid overdoses rose 30% in the US from July 2016 through September 2017; in addition, those with an overdose are more likely to a repeat overdose.
Read Article
Abatacept Efficacy in JIA
Subcutaneous abatacept (Orencia) showed efficacy among children with polyarticular juvenile idiopathic arthritis (JIA) in an open-label phase III trial.
Read Article
Severe Stevens-Johnson and Toxic Epidermal Necrolysis Syndromes May Respond to Etanercept
The Journal of Clinical Investigation reports the results of a trial wherein etanercept (ETN) was shown to be effective in treating cytotoxic T lymphocyte–mediated (CTL-mediated) severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (T
Read Article
The RheumNow Week in Review - 2 March 2018
Dr. Jack Cush reviews the news and highlights from the past week on RheumNow.com.
Read Article
Steroid Use During Rheumatoid Pregnancies
Pregnant women (n=254) with rheumatoid arthritis who enrolled in the MotherToBaby Autoimmune Diseases in Pregnancy Study and who were taking oral glucocorticoids were studied.
Read Article
Inflammatory Arthritis Variants with Checkpoint Inhibitors
Capelli and colleagues have studied patients treated with ICIs and found two variants of inflammatory arthritis (IA) - a reactive arthritis like large joint arthritis with combination ICI therapy or a small joint IA with ICI monotherapy.
Read Article
2017 Rheumatology Year in Review
This retrospective review is drawn from the authors collection of the most impactful publications, research and news that occurred in 2017. In no particular order, here are my top rheumatology advances, news and research reports for calendar year 2017.
Read Article
IL-18 Binding Protein Effective in Adult-Onset Still's Disease
Gabay and colleagues have reported the results of a novel new recombinant human IL-18 binding protein, tadekinig alfa, demonstrating its effectiveness in an open-label dose escalating study in patients with adult-onset Still's disease (AOSD).
Read Article
